ALS Clinical Trial
Official title:
Genomic Translation for Amyotrophic Lateral Sclerosis Care
The purpose of this study is to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progress with a particular pattern.
In all patients, ALS/MND is caused by the progressive death of motor neurons. However, every patient is affected differently. Some develop symptoms in their 80's while others get sick in adolescence. Swallowing/speech are affected first in some patients, but most have weakness in their hands or feet at onset. Some individuals show very rapid progression, even as others live for decades. Finally, some patients have loss of mainly motor neurons in the brain (as in primary lateral sclerosis), while others lose mainly lower motor neurons in the spinal cord and brain stem (as in progressive muscular atrophy). Research has uncovered a few genetic factors that contribute to the variability of ALS/MND. For example, mutations in the superoxide dismutase 1 (SOD1) gene makes onset in the legs more likely and decreases the chance of developing dementia. Conversely, having a mutated C9ORF72 gene makes dementia much more likely. Uncovering additional factors causing ALS variability is an important research priority and is likely to provide clues about how to better diagnose and treat the disease. This study is called "Genomic Translation for ALS Care" (GTAC). The investigators will analyze the genome and gene expression patterns of people with ALS/MND and carry out research on that data, finding insights that the investigators hope will translate into better care for ALS/MND patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
| Completed |
NCT02405182 -
MRI Biomarkers in ALS
|
||
| Completed |
NCT00696332 -
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT03865420 -
Amyotrophic Lateral Sclerosis (ALS) Families Project
|
||
| Terminated |
NCT04054141 -
rTMS in Treatment of Spasticity
|
N/A | |
| Recruiting |
NCT03272503 -
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT05568615 -
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
|
Phase 3 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Active, not recruiting |
NCT04259255 -
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
|
||
| Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A | |
| Completed |
NCT02525471 -
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1 | |
| Recruiting |
NCT05031351 -
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
|
Phase 2 | |
| Active, not recruiting |
NCT05581771 -
Factors Associated With Success of NIPPV in ALS Patients
|
||
| Active, not recruiting |
NCT03268603 -
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Recruiting |
NCT05271435 -
Digital Tools for Assessment of Motor Functions and Falls in ALS
|
||
| Completed |
NCT06005506 -
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
|
N/A | |
| Recruiting |
NCT04138095 -
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
|
N/A | |
| Recruiting |
NCT03698149 -
ECoG BMI for Motor and Speech Control
|
N/A | |
| Not yet recruiting |
NCT05621213 -
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
|
N/A | |
| Terminated |
NCT03373981 -
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS
|
N/A |